Europe Infectious Disease Diagnostics Market to Reach $7,900.4 Million by 2031
10% Free customization
This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Europe infectious disease diagnostics market was valued at $1,394.3 million in 2020 and is expected to reach $7,900.4 million by 2031, witnessing a CAGR of 16.48% during the forecast period 2021-2031.
Market Report Coverage - Europe Infectious Disease Diagnostics
Market Segmentation
- Product (system, kits and reagents, and software)
- Testing location (laboratory testing and point-of-care testing)
- Technology (next-generation sequencing (NGS), polymerase chain reaction (PCR), immunodiagnostics, isothermal nucleic acid amplification technology (INAAT), microarray, in-situ hybridization (ISH), and other technologies)
- Infectious Disease Type (bacterial infectious diseases, viral infectious diseases, fungal infectious diseases, and other infectious diseases)
- Infection Type (respiratory infections, hospital-acquired infections (HAI), sexually transmitted infections (STIs), and other infections)
- End User (hospitals, diagnostic centers, out-patient clinics/general practitioners, research laboratories, and other end users)
Regional Segmentation
- Europe-5 - Germany, U.K., France, Italy and Spain
- Nordic- Denmark, Sweden, Norway and Finland
- Baltic- Estonia, Lithuania and Latvia
- Rest-of-Europe
Market Growth Drivers
- Increasing Prevalence of Infectious Diseases
- Technological Innovation Resulting in Market Pull
- Significant External Funding Supporting Market Growth
Market Challenges
- Uncertain Reimbursement Scenario
- Lack of High Complexity Testing Centers
- Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests
Market Opportunities
- Massive Scope for Adoption of Infectious Disease Diagnostics in Emerging Nations
- Technological Advancements in Molecular Techniques and Infectious Diagnostic Tests
Key Companies Profiled
Abbott, Agilent Technologies, Inc., Becton, Dickinson and Company (BD), bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher, F. Hoffmann-La Roche Ltd, Illumina, Inc., QIAGEN N.V., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., PerkinElmer Inc., Hologic Inc. (Mobidiag Ltd.), Abacus Diagnostica Oy, Novacyt Group, Biocartis
Key Questions Answered in the Report
- How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment?
- What are the major market drivers, challenges, and opportunities in the Europe infectious disease diagnostics market?
- What are the underlying structures resulting in the emerging trends within the Europe infectious disease diagnostics market?
- How is each segment of the Europe infectious disease diagnostics market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?
- What are the key developmental strategies implemented by the major players to sustain in the competitive market?
- What are the key regulatory implications in developed and developing regions for molecular diagnostics?
- Who are the leading players with significant offerings to the Europe infectious disease diagnostics market? What is the current market dominance for each of these leading players?
- What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which infectious disease product type is anticipated to have the most promising growth?
- What are the key applications in the Europe infectious disease diagnostics market? What are the major segments of these applications? What technologies are dominating these application segments?
- What are the major technologies that are employed in the Europe infectious disease diagnostics market? Which is the dominating technology?
- Who are the primary end users of the Europe infectious disease diagnostics market? Which is the fastest-growing end-user segment in the Europe infectious disease diagnostics market?
- Who are the key manufacturers in the Europe infectious disease diagnostics market, and what are their contributions? Also, what is the growth potential of each major infectious disease diagnostics manufacturer?
- What is the scope of the Europe infectious disease diagnostics market in the EU’5, Baltic, and Nordic regions? Which infectious disease diagnostics product and end user dominate these regions?
- What are the emerging trends in the Europe infectious disease diagnostics market? How are these trends revolutionizing the diagnostic procedure?
- Which technologies are anticipated to break through the current infectious diseases diagnostic regime?
- Which companies are anticipated to be highly disruptive in the future and why?
- What are the regulatory procedures required to unify the approval process for emerging infectious disease diagnostics? How will these enhance the reimbursement scenario?
- What are the gaps in regularizing optimum infectious disease diagnostics adoption in regular healthcare routines? How are these gaps being tackled?
Market Overview
The use of infectious disease diagnostics kits, assays, and other consumables has increased due to the rising prevalence of cancer, the increasing key player initiatives, and the rising government initiatives. The increasing investments by healthcare companies to meet industry demand and the growing adoption of infectious disease diagnostics kits, tubes, and reagents among major end users are major factors propelling the growth of the Europe infectious disease diagnostics market. The Europe infectious disease diagnostics market was valued at $1,394.3 million in 2020 and is expected to reach $7,900.4 million by 2031, witnessing a CAGR of 16.48% during the forecast period 2021-2031.
Competitive Landscape
The Europe infectious disease diagnostics market comprises well-established and newly emerging companies. Several companies are attempting to sustain their position in the market by launching new products and raising funds to develop new products for infectious disease diagnostics from different product types. Key market players of the Europe infectious disease diagnostics market witnessed product launch and approval, business funding, and synergistic activities from January 2018 to March 2022. The inclination of companies toward product launches suggests that companies are constantly bringing new products to the market to test viral and bacterial infections, which is primarily attributed to an increase in demand for kits and assays by end users.
Table of Contents
1 Markets
2 Products
3 Testing Location
4 Technology
5 Infectious Disease Type
6 Infection Type
7 End User
8 Regions
9 Company Profiles
List of Figures
List of Tables
Executive Summary
he Europe infectious disease diagnostics market was valued at $1,394.3 million in 2020 and is projected to reach $7,900.4 million by 2031, reveals the premium market intelligence study by the publisher. The study also highlights that the market is set to witness a CAGR of 16.48% during the forecast period 2021-2031.In the comprehensive study of the Europe infectious disease diagnostics market, the publisher extensively covers the following:
- Market numbers on micro-segments influencing the market
- Market share analysis of key market players
- Growth share analysis of technology
- Impact of COVID-19 on the Europe infectious disease diagnostics market
- Growth analysis by product, testing center, infectious disease type, infection type, technology, end user, and region
- Detailed company and product profiling for 16 companies
Besides these parameters, the study also encompasses the market growth drivers, market restraining factors, opportunities, competition mapping, and segmental analysis.
The publisher study indicates that the growing prevalence of cancer, strategic initiatives by key market players, and the rise in microbial sequencing are major factors anticipated to contribute to the growth of the Europe infectious disease diagnostics market.
This study highlights the following in the report:
- Emerging opportunities in the infectious disease diagnostics market
- Impact of COVID-19 on the Europe infectious disease diagnostics market
- Market scenario for infectious disease diagnostics kits and reagents
- Drivers promoting the growth of the market
Data from different segments of the market has been analyzed minutely to gain a holistic view of the market. The market has been segmented based on product, technology, infectious disease type, infection type, testing location, end user, and region. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.
To emphasize the dominance of the Europe infectious disease diagnostics market for technologies such as polymerase chain reaction (PCR), next-generation sequencing (NGS), isothermal nucleic acid amplification technology (INAAT), microarray, immunodiagnostics, in-situ hybridization (ISH), and other technologies in 2020 and 2031, Nitish Kumar Singh ,Senior Analyst with the publisher states, “The reason for market growth can be attributed to the highly increasing prevalence of infectious diseases, the technological innovation resulting in the market pull, and the significant external funding supporting market growth. Biomarkers such as viruses and fungi released from normal and infectious cells contain valuable information. The development of novel diagnostic technologies by the legacy and emerging companies with potential advantages followed by the active involvement of the regulatory authorities in issuing approvals is anticipated to augment the growth of the underlying Europe infectious disease diagnostics market in the forthcoming years.”
Key insights are drawn from in-depth interviews with key opinion leaders of 16 leading companies, market participants, and vendors. Key players operating in the Europe infectious disease diagnostics market include Abbott, Agilent Technologies, Inc., Becton, Dickinson and Company (BD), bioMérieux SA, Bio-Rad Laboratories, Inc., Perkin Elmer Inc., Biocartis, Danaher, F. Hoffmann-La Roche Ltd, Illumina, Inc., QIAGEN N.V., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., Novocyte Group., Hologic Inc., (Mobidiag Ltd.), and Abacus Diagnostica Oy.
Who should buy this report?
- Manufacturers of infectious disease diagnostics kits, assays, instruments, and other consumables
- Pharmaceutical and biotechnology companies
- Research and academic institutions
Insightful Questions Covered to Enable Companies to Take Strategic Decisions
How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments:
- Product (system, kits and reagents, and software)
- Testing location (laboratory testing and point-of-care testing)
- Technology (next-generation sequencing (NGS), polymerase chain reaction (PCR), immunodiagnostics, isothermal nucleic acid amplification technology (INAAT), microarray, in-situ hybridization (ISH), and other technologies)
- Infectious Disease Type (bacterial infectious diseases, viral infectious diseases, fungal infectious diseases, and other infectious diseases)
- Infection Type (respiratory infections, hospital-acquired infections (HAI), sexually transmitted infections (STIs), and other infections)
- End User (hospitals, diagnostic centers, out-patient clinics/general practitioners, research laboratories, and other end users)
- Region (EU-5, Baltic, Nordic, and Rest-of-Europe)
- What are the major market drivers, challenges, and opportunities in the Europe infectious disease diagnostics market?
- What are the underlying structures resulting in the emerging trends within the Europe infectious disease diagnostics market?
- How is each segment of the Europe infectious disease diagnostics market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?
- What are the key developmental strategies implemented by the major players to sustain in the competitive market?
- What are the key regulatory implications in developed and developing regions for molecular diagnostics?
- Who are the leading players with significant offerings to the Europe infectious disease diagnostics market? What is the current market dominance for each of these leading players?
- What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which infectious disease product type is anticipated to have the most promising growth?
- What are the key applications in the Europe infectious disease diagnostics market? What are the major segments of these applications? What technologies are dominating these application segments?
- What are the major technologies that are employed in the Europe infectious disease diagnostics market? Which is the dominating technology?
- Who are the primary end users of the Europe infectious disease diagnostics market? Which is the fastest-growing end-user segment in the Europe infectious disease diagnostics market?
- Who are the key manufacturers in the Europe infectious disease diagnostics market, and what are their contributions? Also, what is the growth potential of each major infectious disease diagnostics manufacturer?
- What is the scope of the Europe infectious disease diagnostics market in the EU’5, Baltic, and Nordic regions? Which infectious disease diagnostics product and end user dominate these regions?
- What are the emerging trends in the Europe infectious disease diagnostics market? How are these trends revolutionizing the diagnostic procedure?
- Which technologies are anticipated to break through the current infectious diseases diagnostic regime?
- Which companies are anticipated to be highly disruptive in the future and why?
- What are the regulatory procedures required to unify the approval process for emerging infectious disease diagnostics? How will these enhance the reimbursement scenario?
- What are the gaps in regularizing optimum infectious disease diagnostics adoption in regular healthcare routines? How are these gaps being tackled?
Companies Mentioned
- Agilent Technologies, Inc.
- Becton, Dickinson and Company (BD)
- bioMérieux SA
- Bio-Rad Laboratories, Inc.
- Danaher
- F. Hoffmann-La Roche Ltd
- Illumina, Inc.
- QIAGEN N.V.
- Siemens Healthcare GmbH
- Thermo Fisher Scientific Inc.
- PerkinElmer Inc.
- Hologic Inc. (Mobidiag Ltd.)
- Abacus Diagnostica Oy
- Novacyt Group
- Biocartis
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 262 |
| Published | April 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 1718.3 Million |
| Forecasted Market Value ( USD | $ 7900.4 Million |
| Compound Annual Growth Rate | 16.5% |
| Regions Covered | Europe |
| No. of Companies Mentioned | 15 |
